We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+12.67%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$701M
AUM Growth
+$112M
Cap. Flow
+$80.1M
Cap. Flow %
11.43%
Top 10 Hldgs %
45.26%
Holding
159
New
30
Increased
40
Reduced
26
Closed
28

Top Buys

Rank Stock Value
1
CEL
Cellcom Israel, Ltd.
CEL
+$14.1M
2
AGN
Allergan plc
AGN
+$14M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$9M
4
MRK icon
Merck
MRK
+$6.67M
5
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$6.17M

Top Sells

Rank Stock Value
1
NVS icon
Novartis
NVS
+$16M
2
BMY icon
Bristol-Myers Squibb
BMY
+$13.8M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$12.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$3.99M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$3.63M

Sector Composition

Rank Sector Weight
1 Healthcare 62.92%
2 Technology 5.67%
3 Communication Services 2.64%
4 Industrials 1.06%
5 Financials 1.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTMX icon
51
CytomX Therapeutics
CTMX
$675M
$3.82M 0.54%
210,000
+10,000
+5% +$156K
KDMN
52
DELISTED
Kadmon Holdings, Inc.
KDMN
$3.69M 0.53%
+1,100,000
New +$3.14M
PDSB icon
53
PDS Biotechnology
PDSB
$38.4M
$3.58M 0.51%
16,687
+9,187
+122% +$1.9M
CRVS icon
54
Corvus Pharmaceuticals
CRVS
$1.12B
$3.53M 0.5%
221,430
-36,235
-14% -$501K
STML
55
DELISTED
Stemline Therapeutics, Inc.
STML
$3.33M 0.48%
300,000
– –
CYTK icon
56
Cytokinetics
CYTK
$10.5B
$3.31M 0.47%
227,990
+10,000
+5% +$137K
VRTX icon
57
Vertex Pharmaceuticals
VRTX
$121B
$3.17M 0.45%
+20,823
New +$3.13M
UNP icon
58
Union Pacific
UNP
$174B
$3.15M 0.45%
27,156
-15,244
-36% -$1.63M
PANW icon
59
Palo Alto Networks
PANW
$270B
$3M 0.43%
+124,830
New +$2.84M
SEDG icon
60
SolarEdge
SEDG
$2.51B
$2.91M 0.42%
102,003
-69,015
-40% -$1.74M
SNDX icon
61
Syndax Pharmaceuticals
SNDX
$1.69B
$2.91M 0.41%
248,472
-47,838
-16% -$586K
ANAB icon
62
AnaptysBio
ANAB
$1.58B
$2.8M 0.4%
+80,000
New +$2.16M
CASC
63
DELISTED
Cascadian Therapeutics, Inc.
CASC
$2.79M 0.4%
681,210
– –
AXSM icon
64
Axsome Therapeutics
AXSM
$11.2B
$2.78M 0.4%
501,000
– –
CMTA
65
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$2.75M 0.39%
+163,000
New +$2.66M
FSTX
66
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$2.69M 0.38%
39,854
-3,896
-9% -$223K
BOLD
67
DELISTED
Audentes Therapeutics, Inc
BOLD
$2.66M 0.38%
95,000
-55,000
-37% -$1.19M
CTIC
68
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$2.66M 0.38%
+833,633
New +$2.78M
SMMT icon
69
Summit Therapeutics
SMMT
$10.4B
$2.65M 0.38%
212,018
+70,000
+49% +$907K
CLSD
70
DELISTED
Clearside Biomedical
CLSD
$2.62M 0.37%
20,000
– –
OVID icon
71
Ovid Therapeutics
OVID
$414M
$2.62M 0.37%
305,674
– –
PRQR icon
72
ProQR Therapeutics
PRQR
$243M
$2.57M 0.37%
530,000
+200,000
+61% +$1.04M
CMCSA icon
73
Comcast
CMCSA
$85B
$2.55M 0.36%
+66,360
New +$2.61M
ADMS
74
DELISTED
Adamas Pharmaceuticals
ADMS
$2.44M 0.35%
115,500
-80,000
-41% -$1.47M
NOMD icon
75
Nomad Foods
NOMD
$1.66B
$2.43M 0.35%
166,662
-101,410
-38% -$1.48M
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2017 Portfolio in Review

As of Q3 2017, Sphera Funds Management held 159 positions worth $701M, up 19% from $589M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management deployed $80.1M of net new capital in Q3 2017, opening 30 new positions and adding to 40 existing holdings. Its largest new stake was Cellcom Israel, Ltd.: 1,535,988 shares worth $14.3M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 66% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Caesarstone, an estimated $3.28M trimmed.

  • Sphera Funds Management's largest Q3 2017 buy was Cellcom Israel, Ltd.: 1,535,988 shares worth $14.3M.
  • Sphera Funds Management added most to Merck in Q3 2017, an estimated $6.67M increase.
  • Sphera Funds Management's biggest Q3 2017 reduction was Caesarstone, cutting an estimated $3.28M.
  • Sphera Funds Management fully exited Novartis in Q3 2017, selling an estimated $16M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $701M portfolio in Q3 2017.
  • Sphera Funds Management opened 30 new positions and closed 28 in Q3 2017.
  • Sphera Funds Management's portfolio value rose 19% quarter-over-quarter to $701M.

Based on Sphera Funds Management's 13F filing for Q3 2017, filed 9 Nov 2017.